Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

cytomegalovirus, pneumonitis
Mo.B. I225, No.A. 1061, Th.A.39 1,
Th.8.300, Th.B.30 I 16.8.302, 16.B.4 I146,
46.B.4200, TU.B.2 182, We.B.3 165,
Weo.8.32 I 7
cytomegalovirus, retinitis
No.8. 1218, No.B.12 19, Mo.B.1223,
Mo.B. 1226, Ne.C. I459,Th.A.39 1,
Th.A.393, lh.A.394, 16.8.300, Th.8.302,
T.8.303.Th.8.304,T6.B.306,Th.B.4 193,
16.8.4 I95, 1.8.41 99, 1h.B.4202,
T h.8.4234, Th.B.43 32, -T.B.2 I85,
[u.B.2 I190, We.8.31I65, We.B.32 I12,
We.8.32 I15, We.8.32 I16, We.B.32 18.
We.C.344 /
cytomegalovirus, treatment, SEE also
individual drugs
Mo.A.1061, Mo.A. 1107, No..1190,
Mo.B.1218. Mo.B.1220, No.8.1221,
No B 122 3,168.302, I-hi B.304,Th.8.4 193,
[-6.8.4194, T6.B.41I96, Th.8.420,
[1,.8.4226, T16.8.4332,1ou.8.2 186,
Tu.8.218 7, To.B.2191. We.8 170,
We.8.32 16 We.8.321I8, We.B.3233
cytopathic effect
Mo.A. 1 098, No.8. 1343, 16.8.4338,
1.A. I 4 2, Tu.A.2 0 19, Tu.A.2040
cytopenia
No..1I29 I1, lu.B.2356
cytotoxic T tells
Mo.A. 1045. Mo.A. 141, Mo.A.I SO,
No.A. I56, N(.A.28 I, No.A.39 I,
No.A.392. No.A.393, No.A.400,
No.A.52 I, No.8.1I284, Pob.8. 105 I,
ih.A. 104, [h.A. I140, Th.A. 141,Th.A. 142,
1 h.A.1I43, 1h.A. I146,3 h.A.1I4/7,uA.1I6 I,
4u.A.2 I100. 1o.A.280, Tu.A.28 I, To.A.282,
4u.A.284, Tu.A.2 85, 4.C.55 3,Tu.D.2737,
We.A. 102, We.A. 3002, We.A.3030,
We.A.3035, We.A.3036, We.A.3038,
We.A.3079, We.A.3080, We A.403,
We.B.3 I10, We.B.3372, We 8.3373
tytotoxitity, HIV
N o.B.120,NMo.B.1256,1Tu.A.280,
We.A.101, We.A.3035, We.A.3080,
We B I 195, We.8.3245, We.D.3682
d4T, SEE stavudine
[-e.A.4042,16 8B293. We 8.3120
dapsone
[ii8 18 I,IouB.2289
dapsone-trimethoprim
[i.8. 112
daraprim
5LJ.181
ddC, SEE zalcitabine
No.A.1I068, MNo.B. 1 134, MNo.8. II4 2,
WAe.. 81 38.We.D3771.,We.D.3806
ddl, SEE didanosine
No.8 1134, T.A.4042, [0.8.293,
168.301. We83 1 38
death and dying
Nc) B. 1159, No B.1162, MNo.8. 13 13,
No.A-).18/9,Bob..1484, Po6.[).1486,
I ub. [3 a1l [68 192,16.8. 196,[6.8. 197,
16.8.4119,108 4318, 16.C.4396,
6 [334896, I 6 [3507 I1, lh.[3.5096,
[6.D.566, [6[3D5169,I viD.5 170,

We.D.355

defective viral particles
Tu.AS 13
delavirdine
No.A. I1103, No.8. 11I34, No.8.295
delirium
No.D. 1889
dementia
No.8.313, No.C. I1575, Th.A.4044,
16.8.426 I,Th.D.5 I 57,Tu.B.2265,
1u.B.2325. We.B.3287, We.B.3289,
We.B.3308
demographic impact
No.C.45 I, Pub.C. I1I60, Pub.C. I1242,
Pub.C. I 246,16.D.4967, We.D.3850
demography
No.C.1415, No.C.1418, No.C.1495,
No.C. 1542, NoC. 1544, NoD. 1763,
Pub.C. I1I09, Pub.D. I1352,[h.C.46 I16,
16.D.4965,Tu.B.2 I 37,Tu.B.2 I147,
To.D.2749
demyelinisation
No.C. 1489
dendritic cells
Th.A. 100,16h.8.4 182,lTu.A.2049,lou.A.39 I
denial
No.D. I1882, Th.C.4639, T6.D.4864,
1h.D.5083, 16.D.5089,lTu.D.2920,
To.D.46 I
dentists, SEE health care personnel
Bub.B. I 069, Th. B.4276, Th.C.4783,
T6.D.5 I161, We.D.3636
deoxyribose
Bob.D. I1446, Th.C.4744
depression
No.B.1201, No.C. 1575, No.D. I1882,
No.D.363, Pub.D. I 499,Th.D.507 I,
Th.D.5098, Th.D.5 I 59,lh.D.5 I162,
Tu. B. 2342,Tu. C.2479,T. C.25 33,
We.B.33 I12, We.D.370, We.D.37 16,
We.D.372
developing countries, SEE also
geographical regions
No.A.520, No.8.1 148, No.8. 11I8 I,
No.C. 1426, No.C. 1442, No.C. 1627,
No.C. 1628, No.C. 1633, No.C.2 13,
No.D, 1762, No.D. 1932, No.D. 1950,
No.D.475, Bub.B. 1037, Pob.B. 1086,
Pub.C. I1I44, Pub.C. I1I45, Pub.C. I1I62,
Bob.C.1251I, Pub.C. 1253, Bub.C. 1272,
Pub.C. I128 I, Pub.C. I1282, Pub.C. I1283,
Bub.D. 1306, Pub.D. I1333, Pub.D. I1349,
Bob.D. 1376, Pub.D. 1408, Pub.D. I1434,
Pub.D. I 497,Th.B.400,Th.B.4 159,
16.8.4282,16h.8.430 I,16.8.4302,
Th.C.4 I13, Th.C.420, Th.C.4398,
Th.C.44 I I, Th.C.4727, Th.C.476 I,
16.C.4822, lh.C.4843,lTh.C.4845,
Th.D.234,Th.D.450,Th.D.490 I,
Th.D.500 I,Th.D.5200,Tu.C.2446,
To.C.2506,Tu.C.45 I,To.D.27 I15,
Tu.D.284 I,Tu.D.2849,u.D.2904,
To.D.2939,Tu.D.46 I, We.C. 120,
We.C.3433, We.C.3474, We.C.3577,
We.D.230, We.D.3634, We.D.367 1,
We.D.3672, We.D.3675, We.D.3676,
We.D.368 I, We.D.3744, We.D.3748,
We.D.3803, We.D.3806, We.D.3847,

diagnosis
No.A. 160, No.A. 162, No.A.5 13,
No.8.1 181, No.8.1208, No.8.12 19,
No.8. I1226, No.8. 13S5, No.8.3 I5,
No.C. 1402,. NoC. 1635, No.C. 1637,
Mo.C. I1642, Bob.B. 1041, Pub.B. I1044,
Bub.B. 1069, Pub.B. I1093, Pub.B. I1094,
T6.A.395, Th.A.40 I10, Th.A.40 12,
Th.A.40 I16, T6.A.40 I17, Th.A.4034,
Th.A.4046, Th.A.4047,16h.A.4048,
Th.A.4050,1Th.A.4073,16h.A.4074,
Th.A.4076,T6.B. 1I 8,16.8. I82,16.8.4 I155,
Th.8B.4 158,T6.8B.4 159,Th.8B.4 163,
16.B.4203,Th.B.4256,Th.B.4263,
Th.B.4283,Th.B.4305,T6.C.4809,
le.A. ISO, 1e.A.2023, 1o.A.2085,
Tu.A.2086,Tu. B. 1I0I TuoB. I1I4,Tu. B. 115,
Tu. B.2 I164,Tu. B.2 I168,Tu. B.2 I169,
Te.B.2235,To.B.2374,Te.C.2582,
We.A. 30 I8, We. B. 3 I68, We. B. 3 I69,
We.B.32 I13, We.B.328 I, We.B.3284,
We.B.3347, We.B.3 3S2, We.B.3355,
We.C.3446, We.D.3606, We.D.36 10
diagnostic criteria
No.1 182, No.8. I1I86, Beb.B. 1080,
Pub.C. I1I50, Th.A.4003, Th.A.4009,
Th.A.4048,Th.B.4 1I,16.8.4228,
Te.B.2 I16 I,lo.B.2222, We.B.3 I167.
We.B.3 I176, We.B.3 I179, We.B.330 1,
We.B.3355, We.D.363 I
diarrhea, diagnosis
No.8. 114, No.. 11IS, No.8.1213,
No.8. I1224, No.8. I1267, Bob.A. 1028,
Beb.B. 1054, Pub.B. I1057, Bob.B. 1068,
Th.A.4030,Ih.A.406 I,Th.A.4073,
Th.8B.4211 I,Th.8B.42 12,Th.8B.42 16.
16.8.4268, We.B.3208, We.B.3220,
We.B.3292, We.B.3294, We.B.3297,
We.B.3298
diarrhea, treatment
No.8.300,16.8.42 II,16.8.42 13,
16.8.42 15,16.B.427 I,16.C.4562,
Te.B.2 I 86,To.B.2366, We.B.3262,
We.B.3297
didanosine (ddl)
No.A. 1076, No.A. 1079, Mo.A. I1I12,
No.8. 1126, No.8. I1I26, No.8. I 143.
No.8. 1306, No.8.1332, No.8.29 I,
No.8.293, No.8.294, No.8.295,
No.B.S33, Beb.A. I1009, Th.A. I1SS,
16.8.290,16.8.29 I,1.8.293,16.8.4244,
16.8.4269,16h.8.4328, 16.8.433S,
Tu. B.211I5,Tu. B.21 16,lTu. B.21 19,
Tu. B.2 I120, Tu. B.2 I148,Tu. B.54 3,
We.A.30 I10, We.A.384, We.B.3 115,
We.8.3 117, We.B.3 118, We.B.3 123,
We.B.3 I124, We.B.3 I139, We.B.532,
We.B.55 I, We.C.3594
dideoxycytidine (ddC), SEE zalcitabine
No.8. 175
dideoxyinosine (ddl), SEE didanosine
Mo.A. I1105, Pub.D. 1346,16.8.4345.
Te.A.265,Tu.B.2 I1I3
dideoxypurine
No.A. 1076
diet
No.B. I1172, No.8. 1388, No.D. I1748,

We.D. 131, We.D.1I32. We.D. 135,
We.D.3605, We.[D.3606, We.D.3608,

We.D.36 I10, We.D.36 I12, We.D.36 13,
We.D.36 14, We.D.36 I5, We.D.3883
discordant couples
No.A.40 I, No.A.402, No.C. 1608,
No.C.57 I, No.D. 171 1,No.D. 1776,
No.D.373, Pub.C. I1I23, Pub.C. I1I52,
16.D.5099,Tu.C.45 I,Tu.D.2698
discrimination
No.C. 1591, NoD. 131, No.D. I134,
No.D. I137, No.D. 1766, No.D. I1882,
No.D.603, Pub.C. I1237, Pub.D. I1302,
Pub.D. I1397, Beb.D. 1398, Peb.D. 14 I12,
Bub.D. 1474, Pub.D. I1476, Pub.D. I1480,
Bub.D. 1483, Bob.D. I1497, Th.C.437 I,
1h.C.4636,16.D.255, 16.D.372,
Th. D.48 76, Th. D.4942,T6. D.494 3,
Th.D.4945,Th.D.495 I,Th.D.4952,
T6.D.4953,Th.D.4983,16.D.4996,
Th.D.5079,Th.D.5083,Th.D.5089,
T6.D.5 I 73,Tu.C.260 I,leD. 131,
Te.D.275 I, le.D.2858,Tu.D.2923,
Tu.D.2954,lu.D.2959, We.C.3576,
We.D.3876, We.D.3883, We.D. 3907,
We.D.61 I
disease progression, SEE progression
No.8. 1171, No.C.1653,16.8.4338,
Tu.A.2069,Tu.8B.2 I188,Tu. B.22 I12,
We.A.284, We.A.305 3. We.B.3252,
We.C.3403, We.C.3407. We.C.3459
DNA binding
No.A. I 099,.16.A.4045. lu.A.2035
DNA, detection
No.8.3 I 1, Pub.A. I 004,16.A.392,
Th.A.4037, u.A, I1S0,ILJ.A.207 1I luoB. I1I5,
Tu.B.2 I 72,Iu.B.2224, We.A.520,
We.C.330. We.C.33 I, We.C.333,
We.C.340, We.C.344
DNA integrated
No.AlO 18, No.A.1022
DNA probe analysis
Mo.A. I164, No.D. 1728,16.8.4207,
16.C.4746, le.A.2096, We.A.3037,
We.C.344
DNA, unintegrated
No.A. 1018
DNCB
Th.8B.4 I174,16h.8B.4 I182
doxorubicin
T6.A.4077,Tu.B.222 I, We.B.3232
drug experimentation
No.A. 1050, No.A. 1057, No.A. 1064,
No.A. 1079, No.A. 1095, No.A. 1098,
Mo.A. I1I01, No.A. I1107, Bub.A. 1022,
Beb.A. 1025, Pub.B. I1032, Ih.A. I150,
T6.A.405 I,Tu.A.2038,Tu.B,2276,
We.B.3 199
drug interactions
No.A. 1095, No.8. 1188, No.8. 1192,
No.8. I1194, No.8. I1196, No.8. I1197,
No.8. 1198, No.8. 1199, No.8. 1200,
No.8 1 201, No.8. 1202, No.8. I171,
No.B. I174, Pub.A. I1022, Pub.C. I1229,
16.B.301I,16.B.4 120,Th.C.225,Th.D.505 I,
Te.B.2 I 34,le.B.4 13, We.B.3364
drug regulation
Peb. D.1407,e. B.21 14
drug resistance, antiretrovirals

No.C. 1425, No.C. 1454, Mo.C. 1590,
No.D.1734, No.D.1910, Peb.C.I1101,

O\
0
La
0
U
c
C
0
0
ci
ci
a)

482